$SKYE

$1.45 -$0.12 (7.64%) Close

$SKYE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 35.4M shares outstanding

Who owns SKYE?

By type of holder

Institutions 45.2% Insiders 11.2% Everyone else 43.5%

Concentration Top 10 holders own 59.1%

5AM Venture Management, LLC 27.3% · Versant Venture Management, LLC 5.7%

Institutional ownership

45.2%

-0.3 pts vs last qtr

Institutional holders

+2 vs last qtr

Net shares bought

−106.8K

by institutions in Q2 2026

New / sold out

6 / 4

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Qube Research & Technologies Ltd NEW +43.1K
Northern Trust Corp +36.2K

Biggest sellers in Q2 2026

Millennium Management LLC −59.7K
Geode Capital Management, LLC −59.2K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Skye Bioscience, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+1685.7%

+161.38% a year

Each share's claim on the business

−94.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $17.7M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years99% Under 1 year1%

Quarterly turnover

1.2%

of institutional shares changed hands

Top 10 managers, median time held

2 years

Super Investors

Investment managers reporting SKYE on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
5V 5AM Venture Management, LLC	9.7M	27.33%	Unchanged	2024	2.3%
Shares held by quarter Peak holding9.9M (Q3'24) Change over 8 quarters−231.4K Share of the company27.330% 5AM Venture Management, LLC's full portfolio →
VV Versant Venture Management, LLC	2.0M	5.67%	Unchanged	2024	0.9%
Shares held by quarter Peak holding2.0M (Q3'24) Change over 8 quarters0 Share of the company5.670% Versant Venture Management, LLC's full portfolio →

5AM Venture Management, LLC

9.7M

% of company

27.33%

Change vs last qtr

Unchanged

Held since

2024

Versant Venture Management, LLC

2.0M

% of company

5.67%

Change vs last qtr

Unchanged

Held since

2024

27 more super investors behind a free account

See every manager holding Skye Bioscience, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SKYE on Form N-PORT; together they hold 2.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$390K	561.8K	1.59%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$128K	185.0K	0.52%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$390K

% of company

1.59%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$128K

% of company

0.52%

% of the fund

0.00%

As of

June 30, 2026

8 more funds behind a free account

See every fund holding Skye Bioscience, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
DP Dhillon Punit Insider	1.4M	4.03%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company4.030% Dhillon Punit's insider activity →
AJ Andrew J. Schwab 5%+ holder 13D · 26.1%	1.2M	3.44%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company3.440% Disclosed stake13D · 26.1% View the 13D/G filing →

Dhillon Punit

Insider

1.4M

% of company

4.03%

Change vs last qtr

—

Held since

—

Andrew J. Schwab

5%+ holder13D · 26.1%

1.2M

% of company

3.44%

Change vs last qtr

—

Held since

—

7 more holders behind a free account

See every insider and 5%+ holder of Skye Bioscience, Inc..

Comments